The Exo Iris reportedly combines advanced silicon technology with imaging, workflow software and artificial intelligence (AI) to facilitate multidisciplinary use of point-of-care ultrasound.
Emphasizing ease of use, enhanced imaging quality and artificial intelligence features, Exo has launched the Exo Iris point-of-care ultrasound modality.
In addition to acquiring images with a sweep of one’s wrist via patented SweepAI™ technology, the Exo Iris blends silicon technology with piezoelectric crystals to facilitate rapid delivery of image quality, according to Exo.
The company said other features of Exo Iris include the ability of the ultrasound platform to provide multi-organ scans, assess fine structures and offer guidance for IVs and line procedures.
Key AI features include assessment of bladder volume in seconds with Bladder AI and forthcoming real-time guidance and triage capabilities with Cardiac and Lung AI suites that are pending FDA 510(k) clearance, according to Exo.
“Exo Iris delivers an entirely new approach to the design of ultrasound; one that doesn’t look at ultrasound as a device-only purchase, but seamlessly brings together a complete solution that includes imaging, workflow, and real-time AI in one platform,” noted Arun Nagdev, M.D., the senior director of clinical education at Exo.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.